AstraZeneca Executive and Leadership Team

Gary Teo, the Chief Financial Officer, Cluster (Vietnam, Philippines) at AstraZeneca, manages fiscal health across Southeast Asian markets. Teo directs capital allocation and financial planning to support the commercialization of prescription medicines within these specific regions. By analyzing market trends and regulatory requirements, the Chief Financial Officer, Cluster (Vietnam, Philippines) ensures that regional operations remain profitable while maintaining alignment with global corporate standards. This role involves close collaboration with local leadership to optimize resource distribution and mitigate economic risks. Gary Teo drives financial transparency and accountability, which directly supports the broader mission of delivering innovative therapies to patients. Through rigorous oversight of regional budgets and investment strategies, the Chief Financial Officer, Cluster (Vietnam, Philippines) secures the necessary funding to sustain growth and operational excellence in these critical emerging markets.

Gonzalo Kuri, the Chief Financial Officer, LATAM at AstraZeneca, directs the financial strategy for the entire Latin American region. Kuri oversees fiscal reporting, tax compliance, and investment analysis to ensure the sustainability of the company's commercial presence across diverse markets. By aligning financial goals with the broader biopharmaceutical mission, the Chief Financial Officer, LATAM supports the expansion of oncology and metabolic disease portfolios. This role involves managing complex budgetary requirements and collaborating with regional stakeholders to drive revenue growth and operational efficiency. Gonzalo Kuri executes financial policies that protect assets while fostering innovation in patient care. Through the implementation of robust financial controls, the Chief Financial Officer, LATAM ensures that regional operations contribute effectively to the global bottom line. Kuri maintains a focus on long-term value creation, ensuring that the company remains a leader in providing essential medicines throughout the Latin American landscape.

Kevin Durning, the Chief Financial Officer (US) & Vice President, Finance Biopharmaceuticals at AstraZeneca, oversees the financial health of the largest commercial market. Durning directs fiscal strategy, revenue forecasting, and capital investment for the US biopharmaceuticals division. By managing the financial aspects of the respiratory, immunology, and metabolic disease portfolios, the Chief Financial Officer (US) & Vice President, Finance Biopharmaceuticals ensures that resources align with market demand and patient needs. This role involves close partnership with executive leadership to drive growth and maintain profitability in a highly competitive environment. Kevin Durning executes financial initiatives that support the development and commercialization of prescription medicines. Through rigorous analysis and strategic planning, the Chief Financial Officer (US) & Vice President, Finance Biopharmaceuticals optimizes the financial performance of the US business, ensuring that the company continues to deliver high-value therapeutic solutions to patients across the country.

Santiago Rivera, the Chief Financial Officer & Chief Financial Officer, Andean Cluster at AstraZeneca, manages financial operations across the Andean region. Rivera directs the financial planning, budgeting, and risk management processes necessary to sustain the company's commercial activities in these markets. By overseeing the financial health of the Andean Cluster, the Chief Financial Officer & Chief Financial Officer, Andean Cluster ensures that resources are allocated effectively to support the distribution of prescription medicines. This role involves coordinating with regional teams to drive operational efficiency and financial stability. Santiago Rivera executes strategies that align local performance with global corporate objectives. Through the implementation of rigorous financial oversight, the Chief Financial Officer & Chief Financial Officer, Andean Cluster supports the company's mission to provide innovative treatments to patients. Rivera maintains a focus on fiscal discipline, ensuring that the Andean operations contribute to the overall growth and success of the global biopharmaceutical enterprise.

Richard Hasselbusch, the Vice President and Chief Financial Officer, Global Operations and Information Technology at AstraZeneca, directs the financial strategy for the company's global manufacturing and IT infrastructure. Hasselbusch oversees the capital investments required to maintain state-of-the-art production facilities and digital systems. By managing the financial performance of global operations, the Vice President and Chief Financial Officer, Global Operations and Information Technology ensures that the supply chain remains resilient and efficient. This role involves collaborating with technology leaders to drive digital transformation and operational excellence. Richard Hasselbusch executes financial policies that support the scaling of production to meet global demand for prescription medicines. Through the oversight of large-scale budgets and technology spending, the Vice President and Chief Financial Officer, Global Operations and Information Technology secures the infrastructure necessary for the company to deliver innovative therapies to patients worldwide, maintaining a focus on long-term operational sustainability.

Joey Zhu, the Chief Financial Officer, PA To The at AstraZeneca, manages specialized financial oversight and executive support functions. Zhu directs the financial analysis and reporting processes that inform high-level decision-making within the organization. By providing critical financial insights, the Chief Financial Officer, PA To The ensures that executive leadership has the data necessary to guide the company's strategic direction. This role involves managing complex financial projects and coordinating with various departments to maintain fiscal integrity. Joey Zhu executes financial strategies that support the company's commitment to science-led biopharmaceutical development. Through the oversight of key financial metrics and operational reporting, the Chief Financial Officer, PA To The contributes to the overall efficiency and success of the business. Zhu maintains a focus on accuracy and strategic alignment, ensuring that financial resources are utilized effectively to support the company's mission of improving patient outcomes through innovative medicine.

David Auerbach, the Strategy, Transformation Operations Leader & Global Chief Operating Officer, Head of Tmo, Oncology Research & Development at AstraZeneca, architects the operational framework for oncology innovation. Auerbach oversees the integration of research and development workflows to accelerate the delivery of life-saving cancer treatments. By streamlining complex processes, the Strategy, Transformation Operations Leader & Global Chief Operating Officer, Head of Tmo, Oncology Research & Development ensures that scientific breakthroughs transition efficiently from laboratory settings to clinical application. This leadership position requires constant coordination with global research teams to maintain a competitive edge in the biopharmaceutical sector. David Auerbach drives organizational transformation by implementing scalable systems that enhance productivity and data-driven decision-making. Through the management of the Transformation Management Office, the Strategy, Transformation Operations Leader & Global Chief Operating Officer, Head of Tmo, Oncology Research & Development optimizes resource utilization to maximize the impact of oncology research on patient health outcomes.

Renee Iacona, the Chief Operating Officer, Oncology Research & Development at AstraZeneca, manages the operational infrastructure supporting the discovery and development of oncology medicines. Iacona directs the daily activities of research teams to ensure that clinical trials and drug development pipelines proceed according to strict timelines and quality standards. By optimizing laboratory workflows and resource allocation, the Chief Operating Officer, Oncology Research & Development facilitates the rapid advancement of innovative therapies. This role requires deep engagement with scientific leaders to align operational capacity with the company's ambitious oncology goals. Renee Iacona drives efficiency across the research lifecycle, ensuring that every stage of development receives the necessary support to succeed. Through the oversight of complex research operations, the Chief Operating Officer, Oncology Research & Development enables the organization to maintain its position at the forefront of cancer treatment, ultimately improving the lives of patients worldwide.

Katharine Oteiza, the Director, BPO - Biometrics Chief of Staff at AstraZeneca, coordinates the operational activities within the biometrics and business process outsourcing functions. Oteiza directs the alignment of data-driven research initiatives with the company's broader biopharmaceutical goals. By managing the flow of information and operational priorities, the Director, BPO - Biometrics Chief of Staff ensures that research teams have the necessary support to analyze clinical data effectively. This role involves facilitating communication between departments to streamline processes and enhance the quality of research outcomes. Katharine Oteiza drives organizational efficiency by overseeing the integration of biometric data into the drug development pipeline. Through the management of complex operational workflows, the Director, BPO - Biometrics Chief of Staff enables the company to maintain high standards of scientific rigor. Oteiza ensures that the biometrics function remains a cornerstone of the research and development strategy, supporting the delivery of innovative medicines.

Beth Clement, the Global HR Business Partner & To HR Chief of Staff at AstraZeneca, directs human capital strategy to support the company's global workforce. Clement oversees talent management, organizational development, and employee engagement initiatives that align with the biopharmaceutical mission. By partnering with leadership across various functions, the Global HR Business Partner & To HR Chief of Staff ensures that the organization attracts and retains the talent necessary to drive scientific innovation. This role involves managing the operational aspects of the HR function to enhance productivity and foster a culture of excellence. Beth Clement executes HR policies that support the growth and development of employees worldwide. Through the coordination of strategic human resources initiatives, the Global HR Business Partner & To HR Chief of Staff enables the company to maintain a high-performing workforce, which is essential for the discovery, development, and commercialization of life-changing prescription medicines.